| Year |
Citation |
Score |
| 2019 |
Safo MK, Pagare PP, Ghatge M, Casu C, Ghiaccio V, Anabaraonye N, Xu X, Rivella S, Hines PC, Liu K, Zhang Y, Venitz J, Abdulmalik O. PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation Blood. 134: 73-73. DOI: 10.1182/Blood-2019-128646 |
0.331 |
|
| 2018 |
Maharao N, Venitz J, Gerk PM. Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability. Biopharmaceutics & Drug Disposition. PMID 30520057 DOI: 10.1002/Bdd.2166 |
0.328 |
|
| 2018 |
Pagare PP, Ghatge MS, Musayev FN, Deshpande TM, Chen Q, Braxton C, Kim S, Venitz J, Zhang Y, Abdulmalik O, Safo MK. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease. Bioorganic & Medicinal Chemistry. PMID 29655608 DOI: 10.1016/J.Bmc.2018.04.015 |
0.306 |
|
| 2017 |
Xu GG, Pagare PP, Ghatge MS, Safo RP, Gazi A, Chen Q, David T, Alabbas AB, Musayev FN, Venitz J, Zhang Y, Safo MK, Abdulmalik O. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease. Molecular Pharmaceutics. PMID 28858508 DOI: 10.1021/Acs.Molpharmaceut.7B00553 |
0.352 |
|
| 2015 |
Xu GG, Deshpande TM, Ghatge MS, Mehta AY, Omar AS, Ahmed MH, Venitz J, Abdulmalik O, Zhang Y, Safo MK. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-releasing prodrugs biotransformation and hemoglobin-NO biochemistry. Biochemistry. PMID 26582149 DOI: 10.1021/Acs.Biochem.5B01074 |
0.302 |
|
| 2014 |
Abdulmalik O, Deshpande T, Ghatge M, Zhang Y, Venitz J, Parikh A, Safo MK. Novel Structurally-Modified Allosteric Effectors of Hemoglobin Exhibit Superior Antisickling Properties Blood. 124: 218-218. DOI: 10.1182/Blood.V124.21.218.218 |
0.355 |
|
| 2013 |
Mulgaonkar A, Venitz J, GrĂ¼ndemann D, Sweet DH. Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrobial Agents and Chemotherapy. 57: 2705-11. PMID 23545524 DOI: 10.1128/Aac.02289-12 |
0.312 |
|
| 2012 |
Mulgaonkar A, Venitz J, Sweet DH. Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters. Expert Opinion On Drug Metabolism & Toxicology. 8: 553-69. PMID 22435536 DOI: 10.1517/17425255.2012.674512 |
0.313 |
|
| 2012 |
Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. Journal of Clinical Pharmacology. 52: 1784-805. PMID 22205719 DOI: 10.1177/0091270011423662 |
0.324 |
|
| 2011 |
Werley MS, McDonald P, Lilly P, Kirkpatrick D, Wallery J, Byron P, Venitz J. Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs. Toxicology. 287: 76-90. PMID 21683116 DOI: 10.1016/J.Tox.2011.05.015 |
0.324 |
|
| 2010 |
Jain L, Gardner ER, Venitz J, Giaccone G, Houk BE, Figg WD. Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 3187-92. PMID 20951100 DOI: 10.1016/J.Jchromb.2010.09.017 |
0.305 |
|
| 2009 |
Venitz J, Brar SS, Pronk GJ, Huntington M, Wilroy S, O'Connor OA, Azzoli CG. Abstract B211: Pralatrexate pharmacokinetics with intravenous administration to oncology patients Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B211 |
0.38 |
|
| 2008 |
Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. Journal of Clinical Pharmacology. 48: 1451-9. PMID 18832294 DOI: 10.1177/0091270008324180 |
0.328 |
|
| 2007 |
Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, Figg WD. Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. Journal of Pharmaceutical Sciences. 96: 1821-31. PMID 17252610 DOI: 10.1002/Jps.20837 |
0.329 |
|
| 2006 |
Lakhani N, Sparreboom A, Venitz J, Dahut WL, Figg WD. Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. Anti-Cancer Drugs. 17: 977-83. PMID 16940808 DOI: 10.1097/01.Cad.0000224447.08706.92 |
0.316 |
|
| 2006 |
Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biology & Therapy. 5: 22-7. PMID 16357512 DOI: 10.4161/Cbt.5.1.2349 |
0.313 |
|
| 2005 |
Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 19: 1176-82. PMID 15818726 DOI: 10.1002/Rcm.1902 |
0.309 |
|
| 2004 |
Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, Figg WD. Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 811: 135-41. PMID 15522712 DOI: 10.1016/J.Jchromb.2004.08.022 |
0.328 |
|
| 2004 |
Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 806: 289-93. PMID 15171941 DOI: 10.1016/J.Jchromb.2004.03.046 |
0.301 |
|
| 2004 |
Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW, Venitz J, Figg WD, Sparreboom A. Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 804: 289-94. PMID 15081922 DOI: 10.1016/J.Jchromb.2004.01.023 |
0.307 |
|
| 2003 |
Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 23: 165-72. PMID 12587805 DOI: 10.1592/Phco.23.2.165.32088 |
0.323 |
|
| 2001 |
Wahr JA, Gerber M, Venitz J, Baliga N. Allosteric Modification of Oxygen Delivery by Hemoglobin Anesthesia and Analgesia. 92: 615-620. DOI: 10.1213/00000539-200103000-00011 |
0.362 |
|
| 1997 |
Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Pearlman AD, Shaw EG, Venitz J, Gerber MJ. 2179 A phase Ib study to evaluate repeated daily intravenous doses of RSR 13 administered to cancer patients receiving concurrent radiation therapy International Journal of Radiation Oncology*Biology*Physics. 39: 330. DOI: 10.1016/S0360-3016(97)80946-7 |
0.318 |
|
| Show low-probability matches. |